ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 240 CHF | +1.35% |
|
+0.84% | -8.19% |
| Apr. 26 | Roche: positive CHMP opinion for Alecensa | CF |
| Apr. 26 | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
| Sales 2024 * | 60.04B 65.63B | Sales 2025 * | 63.83B 69.77B | Capitalization | 178B 195B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.31B 14.55B | Net income 2025 * | 14.75B 16.13B | EV / Sales 2024 * | 3.21 x |
| Net Debt 2024 * | 14.24B 15.56B | Net Debt 2025 * | 8.17B 8.93B | EV / Sales 2025 * | 2.92 x |
| P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
11.8
x | Employees | 103,605 |
| Yield 2024 * |
4.4% | Yield 2025 * |
4.55% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
| 1 day | +1.35% | ||
| 1 week | +0.84% | ||
| Current month | -1.23% | ||
| 1 month | +0.08% | ||
| 3 months | -8.95% | ||
| 6 months | -4.08% | ||
| Current year | -8.19% |
1 week
236.20
250.20
1 month
229.40250.20
Current year
229.40277.40
1 year
229.40318.00
3 years
229.40439.20
5 years
229.40439.20
10 years
209.40439.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 65 | 95-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.06% | 2 M€ | -.--% | - | |
| 2.06% | 2 M€ | +9.19% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 240 | +1.35% | 43,749 |
| 24-04-25 | 236.8 | -1.00% | 41,602 |
| 24-04-24 | 239.2 | -4.40% | 32,173 |
| 24-04-23 | 250.2 | +2.46% | 49,199 |
| 24-04-22 | 244.2 | +2.61% | 41,027 |
Delayed Quote Swiss Exchange, April 26, 2024 at 11:31 am EDT
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
221
CHF
Average target price
279.4
CHF
Spread / Average Target
+26.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +3.00% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -6.26% | 144B | |
| -11.77% | 143B |
- Stock Market
- Equities
- ROG Stock
- RO Stock
